Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Biliary Tract Diseases

Free Subscription Articles published in J Hepatol Retrieve available abstracts of 144 articles: HTML format

Single Articles

July 2026
1. TEN HAAFT BHEA, Bonomi AM, Groot Koerkamp B, Olthof P, et al
   An ABC approach for preoperative staging in perihilar cholangiocarcinoma An international multicenter cohort study.
   J Hepatol. 2026 Jul 24:S0168-8278(26)02740-6. doi: 10.1016/j.jhep.2026.
   PubMed     Abstract available
   
   
   
2. ASSIS DN
   Delphi Consensus in Primary Biliary Cholangitis: Collective Introspection to Set a Forward Path.
   J Hepatol. 2026 Jul 17:S0168-8278(26)02720-0. doi: 10.1016/j.jhep.2026.
   PubMed    
   
   
   
3. XU Q, Zhou S, Zhang C, Zhou Y, et al
   Ivonescimab plus gemcitabine and cisplatin as first-line therapy for advanced biliary tract cancer: a multicenter, open-label phase 2 trial.
   J Hepatol. 2026 Jul 6:S0168-8278(26)02682-6. doi: 10.1016/j.jhep.2026.
   PubMed     Abstract available
   
   
   
4. OH DY, Ikeda M, Macarulla T, He AR, et al
   Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: primary results from the phase IIIb TOURMALINE study.
   J Hepatol. 2026 Jul 6:S0168-8278(26)02658-9. doi: 10.1016/j.jhep.2026.
   PubMed     Abstract available
   
   
   June 2026
5. ROUSIAN M, Alessandris R, Schleimer L, Kalvin H, et al
   Hepatic artery infusion pump chemotherapy for unresectable intrahepatic cholangiocarcinoma: Pooled individual patient-level analysis of four clinical trials.
   J Hepatol. 2026 Jun 22:S0168-8278(26)02655-3. doi: 10.1016/j.jhep.2026.
   PubMed     Abstract available
   
   
   
6. KALAL CR, Gupta P
   Rifaximin and the DCA-serotonin axis in cirrhotic portal hypertension: how much of the benefit is bile-acid specific?
   J Hepatol. 2026 Jun 20:S0168-8278(26)02650-4. doi: 10.1016/j.jhep.2026.
   PubMed    
   
   
   
7. LAMARCA A, Harding JJ, Oh DY
   Systemic therapy of biliary tract cancer: The road to personalised strategies.
   J Hepatol. 2026 Jun 8:S0168-8278(26)00128-5. doi: 10.1016/j.jhep.2026.
   PubMed     Abstract available
   
   
   May 2026
8. CHEW V
   Neoadjuvant GOLP for high-risk resectable intrahepatic cholangiocarcinoma: Shifting the treatment paradigm?
   J Hepatol. 2026 May 29:S0168-8278(26)00286-2. doi: 10.1016/j.jhep.2026.
   PubMed    
   
   
   
9. TRAMPERT DC
   On the use of UDCA beyond cholestatic liver disease: How bile acid-driven intestinal GLP-1 signalling keeps the joints healthy.
   J Hepatol. 2026 May 28:S0168-8278(26)00283-7. doi: 10.1016/j.jhep.2026.
   PubMed    
   
   
   
10. 
    EASL-AASLD Delphi consensus statement on surrogate endpoints and real-world evidence in primary biliary cholangitis.
    J Hepatol. 2026 May 27:S0168-8278(26)00193-5. doi: 10.1016/j.jhep.2026.
    PubMed     Abstract available
    
    
    
11. EATON JE, Erickson BJ, Venkatesh SK
    A call for action: The need to quantify the "-itis" in primary sclerosing cholangitis.
    J Hepatol. 2026 May 26:S0168-8278(26)00290-4. doi: 10.1016/j.jhep.2026.
    PubMed    
    
    
    
12. SCHIRMACHER P, Longerich T
    Histopathology matters for imaging and clinical correlations in Primary Sclerosing Cholangitis.
    J Hepatol. 2026 May 26:S0168-8278(26)00289-8. doi: 10.1016/j.jhep.2026.
    PubMed    
    
    
    
13. GENOVESI V, Salani F, Rimini M, Masi G, et al
    Response to: "Establish a streamlined molecular profiling workflow for the clinical management of advanced cholangiocarcinoma".
    J Hepatol. 2026 May 21:S0168-8278(26)00285-0. doi: 10.1016/j.jhep.2026.
    PubMed    
    
    
    April 2026
14. SABOROWSKI A, Vogel A
    Global biliary tract cancer genomics: from geographic patterns toward biological subtypes.
    J Hepatol. 2026 Apr 28:S0168-8278(26)00225-4. doi: 10.1016/j.jhep.2026.
    PubMed    
    
    
    
15. SUN Q, Ramos SG, Schwabe RF
    Beyond proliferation: YAP shapes the tumor identity and immune landscape of intrahepatic cholangiocarcinoma.
    J Hepatol. 2026 Apr 18:S0168-8278(26)00209-6. doi: 10.1016/j.jhep.2026.
    PubMed    
    
    
    
16. SCHRAMM C, Potter-Lang S, Halilbasic E, Ba-Ssalamah A, et al
    Primary sclerosing cholangitis: time to rethink imaging criteria for early disease detection.
    J Hepatol. 2026 Apr 18:S0168-8278(26)00212-6. doi: 10.1016/j.jhep.2026.
    PubMed    
    
    
    
17. BRAADLAND PR, Ali AH, Puchas P, Juran BD, et al
    Vitamin B6 predicts poor outcomes in geographically distinct populations with primary sclerosing cholangitis.
    J Hepatol. 2026 Apr 17:S0168-8278(26)00203-5. doi: 10.1016/j.jhep.2026.
    PubMed     Abstract available
    
    
    
18. RAMACHANDRAN P
    Assembling a new model to interrogate human liver biliary diseases.
    J Hepatol. 2026 Apr 15:S0168-8278(26)00130-3. doi: 10.1016/j.jhep.2026.
    PubMed    
    
    
    March 2026
19. ZHU Y, Wu JA, Zhang D, Chowdhury S, et al
    Global patterns of mutational profiles in biliary tract cancer.
    J Hepatol. 2026 Mar 28:S0168-8278(26)00157-1. doi: 10.1016/j.jhep.2026.
    PubMed     Abstract available
    
    
    
20. MANCO R, Moliterni C, Neirynck G, Claus R, et al
    Liver Sinusoidal Endothelial Cells and Laminin dictate cholangiocytes' fate in chronic liver disease.
    J Hepatol. 2026 Mar 27:S0168-8278(26)00148-0. doi: 10.1016/j.jhep.2026.
    PubMed     Abstract available
    
    
    
21. LI S, Tong G, Xue M, Shen L, et al
    Activated hepatic stellate cells maintain liver bile acid homeostasis through paracrine FGF10/FGFR2 signaling.
    J Hepatol. 2026 Mar 26:S0168-8278(26)00149-2. doi: 10.1016/j.jhep.2026.
    PubMed     Abstract available
    
    
    
22. PAPADAKOS SP, Argyrou A, Papatheodoridis GV
    Beyond alkaline phopshatase: can anti-integrin alphavbeta6 autoantibodies serve as biomarkers in primary sclerosing cholangitis trials?
    J Hepatol. 2026 Mar 17:S0168-8278(26)00140-6. doi: 10.1016/j.jhep.2026.
    PubMed    
    
    
    
23. ZHAO J, Yang L, Qin Y, Zhang Y, et al
    Distinct molecular pathways regulated by activated AKT and YAP signaling during intrahepatic cholangiocarcinoma progression: Roles of AKT and YAP during iCCA.
    J Hepatol. 2026 Mar 4:S0168-8278(26)00119-4. doi: 10.1016/j.jhep.2026.
    PubMed     Abstract available
    
    
    February 2026
24. JULIEBO AT, Folseraas T, Karlsen TH, Boberg KM, et al
    Differences in Immunosuppressive Strategies for Primary Sclerosing Cholangitis After Liver Transplantation.
    J Hepatol. 2026 Feb 19:S0168-8278(26)00073-5. doi: 10.1016/j.jhep.2026.
    PubMed    
    
    
    
25. CHEN Y, Li J, Lan C
    Establish a streamlined molecular profiling workflow for the clinical management of advanced cholangiocarcinoma.
    J Hepatol. 2026 Feb 15:S0168-8278(26)00076-0. doi: 10.1016/j.jhep.2026.
    PubMed    
    
    
    January 2026
26. XU K, Dong X, Qu H, Hu J, et al
    AF6 knockout-induced upregulation of bile acid production promotes CXCL14-mediated antitumor immunity in HCC: Effect of the BA/Butyrate/CXCL14 axis in HCC.
    J Hepatol. 2026 Jan 21:S0168-8278(26)00016-4. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    December 2025
27. GENOVESI V, Salani F, Rimini M, Rizzato MD, et al
    Molecular profiling and matched targeted treatment in cholangiocarcinoma: results from the Italian dataset (ANITA).
    J Hepatol. 2025 Dec 26:S0168-8278(25)02735-7. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
28. TRAMPERT DC
    Viral infection as a trigger for primary sclerosing cholangitis in genetically susceptible individuals.
    J Hepatol. 2025 Dec 11:S0168-8278(25)02632-7. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
29. KEITEL V, Kreissl MC, Goetze T, Droge C, et al
    CAR T-cell therapy induces remission in multiorgan IgG4-related disease with hepatobiliary involvement.
    J Hepatol. 2025 Dec 8:S0168-8278(25)02711-4. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    November 2025
30. YOON J, Lee CK, Kim JW, Kang B, et al
    Open-label, single-arm, phase 2 trial to investigate the efficacy of sitravatinib plus tislelizumab combination as a second-line treatment for advanced biliary tract cancer.
    J Hepatol. 2025 Nov 24:S0168-8278(25)02626-1. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
31. RODRIGUES PM, Banales JM
    RePARylating biliary tumours to improve the efficacy of chemoimmunotherapy.
    J Hepatol. 2025 Nov 7:S0168-8278(25)02611-X. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
32. FRANCIS H, Glaser S, Ueno Y, Lesage G, et al
    Corrigendum to 'cAMP stimulates the secretory and proliferative capacity of the rat intrahepatic biliary epithelium through changes in the PKA/Src/MEK/ERK1/2 pathway' (J Hepatol 41 [2004] 528-537).
    J Hepatol. 2025 Nov 7:S0168-8278(25)02563-2. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
33. ASSIS DN, Hov JR
    Phase 2 Clinical Trials in Primary Sclerosing Cholangitis: Making the Most of Every Opportunity?
    J Hepatol. 2025 Nov 4:S0168-8278(25)02605-4. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    October 2025
34. MERZ V
    Two lenses, same picture: interpreting nal-IRI in biliary tract cancer.
    J Hepatol. 2025 Oct 17:S0168-8278(25)02560-7. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
35. WONG YJ, Lam L, Soret PA, Lemoinne S, et al
    Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis.
    J Hepatol. 2025 Oct 3:S0168-8278(25)02519-X. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
36. CUI T, Sun L, Guo X, Cheng C, et al
    Tumor-derived CD109 orchestrates reprogramming of tumor-associated macrophages to dampen immune response.
    J Hepatol. 2025;83:946-958.
    PubMed     Abstract available
    
    
    September 2025
37. GALANAKIS V, Gribben C, Munteanu A, Cagna M, et al
    Transcriptomic and epigenetic mechanisms controlling cholangiocytes transdifferentiation into hepatocytes.
    J Hepatol. 2025 Sep 29:S0168-8278(25)02516-4. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
38. YU M, Xie P, Yu Q, Zhao Y, et al
    PARG inhibition halts cholangiocarcinoma progression via the Hippo pathway and enhances response to chemotherapy and immunotherapy.
    J Hepatol. 2025 Sep 26:S0168-8278(25)02500-0. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
39. HIRSCHFIELD GM, Kowdley KV, Trivedi PJ, Eksteen B, et al
    Phase II INTEGRIS-PSC trial of bexotegrast, an alphavbeta6/alphavbeta1 integrin inhibitor, in primary sclerosing cholangitis.
    J Hepatol. 2025 Sep 26:S0168-8278(25)02498-5. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
40. MARONI L, Marzioni M
    Reply to "Time to standardize preoperative EUS for lymph node staging in resectable extrahepatic cholangiocarcinoma".
    J Hepatol. 2025 Sep 18:S0168-8278(25)02481-X. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
41. SUN D, Wang D, Jia L, Wang P, et al
    S1P/S1PR4 Promotes the Differentiation of CD8(+) tissue-resident memory T Cells Aggravating Bile Duct Injury in Biliary Atresia.
    J Hepatol. 2025 Sep 5:S0168-8278(25)02472-9. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    August 2025
42. DIXON ED, Claudel T, Nardo AD, Riva A, et al
    Erratum to 'Inhibition of ATGL alleviates MASH via impaired PPARa signalling that favours hydrophilic bile acid composition in mice' [J Hepatol 82 (2025) 658-675].
    J Hepatol. 2025 Aug 30:S0168-8278(25)02438-9. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
43. SCHWINGE D, Schramm C
    Tregs going acid - how cholestasis impairs regulatory T cell function.
    J Hepatol. 2025 Aug 29:S0168-8278(25)02441-9. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
44. CHAN SL, Lamarca A, Hsu C, Moreno V, et al
    New targets and new drugs for hepatobiliary cancers.
    J Hepatol. 2025 Aug 25:S0168-8278(25)02455-9. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
45. DEL ZOMPO F, Crouchet E, Ostyn T, Nehme Z, et al
    Claudin-1 is a mediator and therapeutic target in primary sclerosing cholangitis.
    J Hepatol. 2025 Aug 20:S0168-8278(25)02440-7. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
46. TRAMPERT DC
    From parts to portal: Recapitulating hepatobiliary microarchitecture using multicellular organoids.
    J Hepatol. 2025 Aug 20:S0168-8278(25)02346-3. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
47. JEONG H, Oh JH, Ahn HS, Ryoo BY, et al
    Proteogenomic profiling predicts outcomes of adjuvant chemotherapy in extrahepatic cholangiocarcinoma.
    J Hepatol. 2025 Aug 11:S0168-8278(25)02402-X. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
48. ZHANG R, Su L, Fu M, Wang Z, et al
    Corrigendum to: 'CD177(+) cells produce neutrophil extracellular traps that promote biliary atresia' (J Hepatol [2022] 77:1299-1310).
    J Hepatol. 2025 Aug 4:S0168-8278(25)02281-0. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
49. HE J, Zhang M, Shi Y, Ji Z, et al
    Targeting xanthine oxidoreductase reverses resistance to EGFR tyrosine kinase inhibitors in intrahepatic cholangiocarcinoma.
    J Hepatol. 2025 Aug 2:S0168-8278(25)02382-7. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    July 2025
50. PU X, Liu Y, Lyu Z, Zhou Y, et al
    B cells drive CCR5(+)CD4(+) tissue-resident memory T cell cytotoxicity via IL-15Ralpha-IL-15 signaling in primary biliary cholangitis.
    J Hepatol. 2025 Jul 17:S0168-8278(25)02340-2. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
51. LIU H, Wang J, Yao Y, Xia T, et al
    Restoration of N-glycosylation via leucine-activated leucyl-tRNA synthetase 1 overcomes chemoresistance in intrahepatic cholangiocarcinoma.
    J Hepatol. 2025 Jul 17:S0168-8278(25)02344-X. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
52. DE JONG DM, Lammers WJ, van Driel LMJW
    Time to standardize preoperative EUS for lymph node staging in resectable extrahepatic cholangiocarcinoma.
    J Hepatol. 2025 Jul 9:S0168-8278(25)02332-3. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
53. VOGEL A, Saborowski A
    Chasing shadows: navigating surrogate endpoints in biliary tract cancer.
    J Hepatol. 2025 Jul 8:S0168-8278(25)02325-6. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    June 2025
54. BEUERS U, Banales JM, Karpen S, Keitel V, et al
    History and prospects of bile acid therapies.
    J Hepatol. 2025 Jun 20:S0168-8278(25)02277-9. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
55. KUDIRA R, Yang ZF, Osuji I, Damen MSMA, et al
    Bile acids engage the SIPR-STAT3 signaling axis to modulate regulatory T cell responses in fibrosing cholangiopathies.
    J Hepatol. 2025 Jun 20:S0168-8278(25)02271-8. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
56. RODRIGUEZ N, Katzenstein C, O'Kula S, Kushner T, et al
    Use of maralixibat in severe and recurrent intrahepatic cholestasis of pregnancy with concurrent benign recurrent intrahepatic cholestasis (BRIC).
    J Hepatol. 2025 Jun 18:S0168-8278(25)02249-4. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
57. TRAMPERT DC
    Bile acid species as hepatic T lymphocyte response modulators - when bile acids interfere with tumor growth.
    J Hepatol. 2025 Jun 5:S0168-8278(25)00249-1. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
58. CASTET F, Fabregat-Franco C, Bridgewater J, Kim JW, et al
    Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer.
    J Hepatol. 2025 Jun 3:S0168-8278(25)02251-2. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    May 2025
59. GHALLAB A, Mandorfer M, Stirnimann G, Geyer J, et al
    Enteronephrohepatic Circulation of Bile Acids and Therapeutic Potential of Systemic Bile Acid Transporter Inhibitors.
    J Hepatol. 2025 May 23:S0168-8278(25)02207-X. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
60. OH DY, He AR, Qin S, Chen LT, et al
    Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study.
    J Hepatol. 2025 May 15:S0168-8278(25)02201-9. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
61. NIU M, Ding WX
    Overcoming drug resistance by harnessing mitochondrial divisome for treating cholangiocarcinoma.
    J Hepatol. 2025 May 9:S0168-8278(25)02197-X. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
62. LEVY C, Abouda GF, Bilir BM, Bonder A, et al
    Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial.
    J Hepatol. 2025 May 8:S0168-8278(25)00252-1. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
63. OLAIZOLA I, Odriozola-Gimeno M, Olaizola P, Caballero-Camino FJ, et al
    New platinum derivatives selectively cause double-strand DNA breaks and death in naive and cisplatin-resistant cholangiocarcinomas.
    J Hepatol. 2025 May 3:S0168-8278(25)00293-4. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    April 2025
64. 
    EASL Clinical Practice Guidelines on the management of extrahepatic cholangiocarcinoma.
    J Hepatol. 2025 Apr 30:S0168-8278(25)00162-X. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
65. LV GY, Mu WT, Cao YN, Sun XD, et al
    Cisplatin-induced Disruption of Mitochondrial Divisome Leads to Enhanced Cisplatin Resistance in Cholangiocarcinoma.
    J Hepatol. 2025 Apr 4:S0168-8278(25)00219-3. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    March 2025
66. YOO C, Ueno M, Klumpen HJ, Kelley RK, et al
    Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 study.
    J Hepatol. 2025 Mar 26:S0168-8278(25)00207-7. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
67. YOO C, Saborowski A, Hyung J, Wenzel P, et al
    Liposomal irinotecan for previously treated patients with biliary tract cancer: A pooled analysis of NIFTY and NALIRICC trials.
    J Hepatol. 2025 Mar 25:S0168-8278(25)00169-2. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
68. GHALLAB A, Gonzalez D, Strangberg E, Hofmann U, et al
    Erratum to: 'Inhibition of the renal apical sodium dependent bile acid transporter prevents cholemic nephropathy in mice with obstructive cholestasis' [J Hepatol (2024) 80:268-281].
    J Hepatol. 2025 Mar 15:S0168-8278(25)00140-0. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
69. KOLEV M, Moller B, Berzigotti A, Semmo N, et al
    Upadacitinib for refractory Primary Biliary Cholangitis.
    J Hepatol. 2025 Mar 12:S0168-8278(25)00159-X. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    February 2025
70. TRAMPERT DC
    B cell-depleting anti-CD19 monoclonal antibody holds promise for treating IgG4-related cholangitis.
    J Hepatol. 2025 Feb 27:S0168-8278(25)00070-4. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
71. KNOX JJ, McNamara MG, Bazin IS, Oh DY, et al
    A phase III randomised study of first-line NUC-1031/cisplatin vs. gemcitabine/cisplatin in advanced biliary tract cancer.
    J Hepatol. 2025 Feb 18:S0168-8278(25)00085-6. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
72. HWANG S, Woo S, Kim C, Chon HJ, et al
    Reply to: Correspondence on 'Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer'.
    J Hepatol. 2025 Feb 12:S0168-8278(25)00082-0. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
73. YOO C
    Response to Zhang et al.: Evaluating Clinical Utility of CT DNA Monitoring for Recurrence Prediction in Resected Extrahepatic Cholangiocarcinoma.
    J Hepatol. 2025 Feb 12:S0168-8278(25)00081-9. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
74. XUE X, Liu R, Cai Y, Gong L, et al
    Hyodeoxycholic acid ameliorates cholestatic liver fibrosis by facilitating m(6)A-regulated expression of a novel anti-fibrotic target ETV4.
    J Hepatol. 2025 Feb 4:S0168-8278(25)00055-8. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    January 2025
75. NYHOLM I, Hukkinen M, Lohi J, Sjoblom N, et al
    Accumulation of altered serum bile acids predicts liver injury after portoenterostomy in biliary atresia.
    J Hepatol. 2025 Jan 29:S0168-8278(25)00062-5. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
76. CHUNG T, Oh S, Won J, Park J, et al
    Genomic and transcriptomic signatures of sequential carcinogenesis from papillary neoplasm to biliary tract cancer.
    J Hepatol. 2025 Jan 18:S0168-8278(25)00013-3. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    December 2024
77. ZHANG Y, Wang K, Song Z
    Evaluating Clinical Utility of CT DNA Monitoring for Recurrence Prediction in Resected Extrahepatic Cholangiocarcinoma.
    J Hepatol. 2024 Dec 9:S0168-8278(24)02742-9. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    November 2024
78. WANG K, Chen Y, Li Y
    Evaluating Concordance and Clinical Utility of ctDNA Profiling in Advanced Biliary Tract Cancer.
    J Hepatol. 2024 Nov 15:S0168-8278(24)02715-6. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
79. LUO P, Lin A, Miao K
    Balancing strengths and limitations of ctDNA in advanced biliary tract cancer genomic profiling.
    J Hepatol. 2024 Nov 15:S0168-8278(24)02716-8. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
80. LIU Y, Wei Y, Chen X, Huang S, et al
    Genetic study of intrahepatic cholestasis of pregnancy in Chinese women unveils East Asian etiology linked to historic HBV epidemic.
    J Hepatol. 2024 Nov 13:S0168-8278(24)02708-9. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
81. HENGSTLER JG, Vartak N
    Activating hepatobiliary water channels for gallstone prevention in complicated gallstone disease.
    J Hepatol. 2024 Nov 12:S0168-8278(24)02704-1. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
82. YOO C, Jeong H, Jeong JH, Kim KP, et al
    Circulating tumor DNA status and dynamics predict recurrence in patients with resected extrahepatic cholangiocarcinoma.
    J Hepatol. 2024 Nov 10:S0168-8278(24)02666-7. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    October 2024
83. HWANG S, Woo S, Kang B, Kang H, et al
    Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer.
    J Hepatol. 2024 Oct 21:S0168-8278(24)02641-2. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
84. TALANIAN M, Almeqdadi M, Chen HH
    From dark bile to bright insight: A liver biopsy with advanced fibrosis and severe cholestasis.
    J Hepatol. 2024;81:e147-e150.
    PubMed    
    
    
    
85. YOUNOSSI ZM, Kremer AE, Swain MG, Jones D, et al
    Assessment of fatigue and its impact in chronic liver disease.
    J Hepatol. 2024;81:726-742.
    PubMed     Abstract available
    
    
    September 2024
86. DIXON ED, Claudel T, Nardo AD, Riva A, et al
    Inhibition of ATGL alleviates MASH via impaired PPARalpha signalling that favours hydrophilic bile acid composition in mice.
    J Hepatol. 2024 Sep 30:S0168-8278(24)02577-7. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
87. FUCHS CD, Simbrunner B, Baumgartner M, Campell C, et al
    Bile acid metabolism and signaling in liver disease.
    J Hepatol. 2024 Sep 28:S0168-8278(24)02572-8. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
88. HUO X, Yu Z, Zhao F, Chen Y, et al
    Hepatocyte Aquaporin 8-mediated Water Transport Facilitates Bile Dilution and Prevents Gallstone Formation in Mice.
    J Hepatol. 2024 Sep 24:S0168-8278(24)02563-7. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
89. HENRY L, Younossi ZM
    Fatigue and Patient Reported Outcomes (PROs) in Primary Sclerosing Cholangitis.
    J Hepatol. 2024 Sep 17:S0168-8278(24)02547-9. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    August 2024
90. RAVANBAKHSH N, Genyk Y, Cheng A, Vats D, et al
    Biliary Cirrhosis associated with WDR19-Related Ciliopathy in Siblings.
    J Hepatol. 2024 Aug 18:S0168-8278(24)02475-9. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    July 2024
91. HUANG P, Wei G, Kirkpatrick JD, Lin Y, et al
    Transposon-based oncogene integration in Abcb4(Mdr2)-/- mice recapitulates high susceptibility to cholangiocarcinoma in primary sclerosing cholangitis.
    J Hepatol. 2024 Jul 30:S0168-8278(24)02423-1. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
92. JOHANNES H, Laura B, Bernd L, Anne T, et al
    Fatigue is a symptom of clinical importance in patients with Primary Sclerosing Cholangitis (SOMA.LIV).
    J Hepatol. 2024 Jul 29:S0168-8278(24)02421-8. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    June 2024
93. ESSER H, Kilpatrick AM, Man TY, Aird R, et al
    Primary cilia as a targetable node between biliary injury, senescence and regeneration in liver transplantation.
    J Hepatol. 2024 Jun 13:S0168-8278(24)02302-X. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
94. WU XN, Wang MZ, Zhang N, Zhang W, et al
    Sex-determining region Y gene promotes liver fibrosis and accounts for sexual dimorphism in its pathophysiology.
    J Hepatol. 2024;80:928-940.
    PubMed     Abstract available
    
    
    May 2024
95. MONTANO-LOZA AJ, Lytvyak E, Hirschfield G, Hansen BE, et al
    Prognostic Scores for Ursodeoxycholic Acid-Treated Patients Predict Graft Loss and Mortality in Recurrent Primary Biliary Cholangitis after Liver Transplantation.
    J Hepatol. 2024 May 29:S0168-8278(24)00345-3. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
96. 
    EASL Clinical Practice Guidelines on genetic cholestatic liver diseases.
    J Hepatol. 2024 May 29:S0168-8278(24)00274-5. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
97. REVIEJO M, Lozano E, Marin JJG
    Impact of alternative splicing on cholangiocarcinoma progression through metabolic rewiring-induced epigenetic events.
    J Hepatol. 2024 May 27:S0168-8278(24)00365-9. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
98. KRAUSE J, Schramm C
    Multi-omics characterization of healthy and PSC human liver - what we knew and what we have learned.
    J Hepatol. 2024;80:681-683.
    PubMed    
    
    
    
99. ANDREWS TS, Nakib D, Perciani CT, Ma XZ, et al
    Single-cell, single-nucleus, and spatial transcriptomics characterization of the immunological landscape in the healthy and PSC human liver.
    J Hepatol. 2024;80:730-743.
    PubMed     Abstract available
    
    
    April 2024
100. YANG L, Niu K, Wang J, Shen W, et al
     Nucleolin lactylation contributes to intrahepatic cholangiocarcinoma pathogenesis via RNA splicing regulation of MADD.
     J Hepatol. 2024 Apr 26:S0168-8278(24)00278-2. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     March 2024
101. LEMAIGRE FP
     Planar cell polarity is crucial for proper morphogenesis of the bile ducts.
     J Hepatol. 2024 Mar 26:S0168-8278(24)00217-4. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
102. XU L, Zhang Y, Lin Z, Deng X, et al
     FASN-mediated fatty acid biosynthesis remodels immune environment in Clonorchis sinensis infection-related intrahepatic cholangiocarcinoma.
     J Hepatol. 2024 Mar 18:S0168-8278(24)00199-5. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     
103. RAAB M, Christodoulou E, Krishnankutty R, Gradinaru A, et al
     Van Gogh-like 2 is essential for the architectural patterning of the mammalian biliary tree.
     J Hepatol. 2024 Mar 7:S0168-8278(24)00149-1. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     
104. LIM YZ, Zhu M, Wang Y, Sharma T, et al
     Pkd1l1-deficiency drives biliary atresia through ciliary dysfunction in biliary epithelial cells.
     J Hepatol. 2024 Mar 7:S0168-8278(24)00151-X. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     
105. TOMLINSON JL, Li B, Yang J, Loeuillard E, et al
     Syngeneic Murine Models with Distinct Immune Microenvironments Represent Subsets of Human Intrahepatic Cholangiocarcinoma.
     J Hepatol. 2024 Mar 6:S0168-8278(24)00127-2. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     February 2024
106. YANG Y, Wang J, Wan J, Cheng Q, et al
     PTEN Deficiency Induces an Extrahepatic Cholangitis-Cholangiocarcinoma Continuum via Aurora kinase A in Mice.
     J Hepatol. 2024 Feb 28:S0168-8278(24)00138-7. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     January 2024
107. FAN X, Yang F, Zhou L, Yang L, et al
     Mycophenolate mofetil for the induction of remission in primary biliary cholangitis with predominant features of autoimmune hepatitis.
     J Hepatol. 2024 Jan 31:S0168-8278(24)00097-7. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
108. TANG R, Li Y, Chen R, Ma X, et al
     Reply to "ARID3A variant and the risk of primary biliary cholangitis in a Central European cohort".
     J Hepatol. 2024 Jan 30:S0168-8278(24)00058-8. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
109. NAYAGAM JS, Miquel R, Thompson RJ, Joshi D, et al
     Genetic cholestasis in children and adults.
     J Hepatol. 2024 Jan 30:S0168-8278(23)05305-9. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
110. TRAMPERT DC, Beuers U
     A beneficial response of fetal wound healing gone bad in the bile duct: The overarching cause of biliary atresia?
     J Hepatol. 2024 Jan 4:S0168-8278(23)05372-2. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
111. ZHENG C, Wang L, Zou T, Lian S, et al
     Ileitis promotes MASLD progression via bile acid modulation and enhanced TGR5 signaling in ileal CD8+ T cells.
     J Hepatol. 2024 Jan 3:S0168-8278(24)00004-7. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     November 2023
112. KRUK B, Liebe R, Weber SN, Milkiewicz P, et al
     ARID3A variant and the risk of primary biliary cholangitis in a Central European cohort.
     J Hepatol. 2023 Nov 28:S0168-8278(23)05290-X. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
113. FICKERT P
     Detour of bile acids routes as therapeutic roadmap for cholemic nephropathy.
     J Hepatol. 2023 Nov 25:S0168-8278(23)05283-2. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
114. DIPERI TP, Zhao M, Evans KW, Varadarajan K, et al
     Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.
     J Hepatol. 2023 Nov 14:S0168-8278(23)05274-1. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
115. VAN MUNSTER KN, Bergquist A, Ponsioen CY
     Inflammatory bowel disease and primary sclerosing cholangitis: One disease or two?
     J Hepatol. 2023 Nov 6:S0168-8278(23)05158-9. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
116. GHALLAB A, Gonzalez D, Strangberg E, Hofmann U, et al
     Inhibition of the Renal Apical Sodium Dependent Bile Acid Transporter Prevents Cholemic Nephropathy in Mice with Obstructive Cholestasis.
     J Hepatol. 2023 Nov 6:S0168-8278(23)05235-2. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     October 2023
117. DE JONG IEM, Theise ND, Wells RG
     The space of Mall confirmed in humans: a response to "Portal venous branches as an anatomic railroad for a gut-bile duct axis".
     J Hepatol. 2023 Oct 9:S0168-8278(23)05155-3. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
118. TRUSSONI CE, LaRusso NF
     Macrophages make a difference in cholestatic liver diseases - but how?
     J Hepatol. 2023 Oct 9:S0168-8278(23)05149-8. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
119. MALAKAR S, Mishra P, Paturu R, Verma R, et al
     Primary sclerosing cholangitis with high immunoglobulin-G4.
     J Hepatol. 2023 Oct 7:S0168-8278(23)05153-X. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     September 2023
120. 
     Corrigendum to "EASL-ILCA clinical practice guidelines on the management of intrahepatic cholangiocarcinoma" [J Hepatol (79) (2023) 181-208].
     J Hepatol. 2023 Sep 23:S0168-8278(23)05092-4. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
121. 
     Corrigendum to "EASL clinical practice guidelines on sclerosing cholangitis" [J Hepatol (77) 761-806].
     J Hepatol. 2023 Sep 19:S0168-8278(23)05091-2. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
122. ABERG F, Sallinen V, Tuominen S, Adam R, et al
     Cyclosporine vs. tacrolimus after liver transplantation for primary sclerosing cholangitis - a propensity-score matched intention-to-treat analysis.
     J Hepatol. 2023 Sep 16:S0168-8278(23)05100-0. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     August 2023
123. CHEN R, Huang B, Lian M, Wei Y, et al
     A+T rich interaction domain protein 3a (Arid3a) impairs Mertk-mediated efferocytosis in cholestasis.
     J Hepatol. 2023 Aug 31:S0168-8278(23)05069-9. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
124. LIMOUSIN W, Laurent-Puig P, Ziol M, Ganne-Carrie N, et al
     Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab.
     J Hepatol. 2023 Aug 28:S0168-8278(23)05070-5. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
125. DE JONG IEM, Hunt ML, Chen D, Du Y, et al
     A fetal wound healing program after intrauterine bile duct injury may contribute to biliary atresia.
     J Hepatol. 2023 Aug 21:S0168-8278(23)05060-2. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
126. KERSTEN R, Trampert DC, Herta T, Hubers LM, et al
     IgG4-related cholangitis - a mimicker of fibrosing and malignant cholangiopathies.
     J Hepatol. 2023 Aug 18:S0168-8278(23)05058-4. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
127. GLESSNER JT, Ningappa MB, Ngo KA, Zahid M, et al
     Biliary atresia is associated with polygenic susceptibility in ciliogenesis and planar polarity effector genes.
     J Hepatol. 2023 Aug 10:S0168-8278(23)05040-7. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
128. ROMA K, Mohammed S, Sieck B, Naik K, et al
     Kratom-induced acute liver injury: A case study and the importance of herbal supplement regulation.
     J Hepatol. 2023;79:581-584.
     PubMed     Abstract available
     
     
     July 2023
129. DE MARTIN E, Laurent-Bellue A, Routier E, Samuel D, et al
     Acute cholestatic hepatitis in a patient with metastatic melanoma.
     J Hepatol. 2023;79:e13-e15.
     PubMed    
     
     
     
130. D'ARTISTA L, Moschopoulou AA, Barozzi I, Craig AJ, et al
     MYC determines lineage commitment in KRAS-driven primary liver cancer development.
     J Hepatol. 2023;79:141-149.
     PubMed     Abstract available
     
     
     June 2023
131. ROMEO M, Dallio M, Federico A
     Multidrug Resistance Protein 6 (ABCC6/MRP6) loss of function causing Pseudoxanthoma elasticum (PXE) is associated with Low-Phospholipid Associated Cholelithiasis (LPAC) features: is it time to reconsider the MRP6 role in bile secretion and LPAC geneti
     J Hepatol. 2023 Jun 29:S0168-8278(23)04936-X. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
132. ARINO S, Aguilar-Bravo B, Coll M, Lee WY, et al
     Ductular reaction-associated neutrophils promote biliary epithelium proliferation in chronic liver disease.
     J Hepatol. 2023 Jun 20:S0168-8278(23)00423-3. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
133. ALMAAS R, Atneosen-Asegg M, Ytre-Arne ME, Melheim M, et al
     Aagenaes syndrome/lymphedema cholestasis syndrome 1 is caused by a founder variant in the 5'-untranslated region of UNC45A.
     J Hepatol. 2023 Jun 14:S0168-8278(23)00410-5. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
134. BRAADLAND PR, Bergquist A, Kummen M, Bossen L, et al
     Clinical and biochemical impact of vitamin B6 deficiency in primary sclerosing cholangitis before and after liver transplantation.
     J Hepatol. 2023 Jun 14:S0168-8278(23)00415-4. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
135. LATTANZI B, Covotta F, Cardinale V
     The Potential Role Of Endoscopy Ultrasound In Primary Sclerosing Cholangitis.
     J Hepatol. 2023 Jun 9:S0168-8278(23)00404-X. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     May 2023
136. TOMLINSON JL, Valle JW, Ilyas SI
     Immunobiology of Cholangiocarcinoma.
     J Hepatol. 2023 May 16:S0168-8278(23)00338-0. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
137. BOLDUAN F, Geisel D, Pahl S, Wree A, et al
     Painless jaundice with segmental obstructive cholestasis.
     J Hepatol. 2023 May 9:S0168-8278(23)00209-X. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     April 2023
138. GRADY J, Clifford C, Treadwell MC, Parikh ND, et al
     The Use of Fenofibrate for Intrahepatic Cholestasis of Pregnancy.
     J Hepatol. 2023 Apr 19:S0168-8278(23)00237-4. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
139. DANA J, Debray D, Vilgrain V
     Reply to: "The effects of CFTR modulator therapies on liver stiffness and bile flow: a single centre experience".
     J Hepatol. 2023 Apr 10:S0168-8278(23)00222-2. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
140. FICKERT P, Lin AC, Ritschl H, Hammer N, et al
     Portal venous branches as an anatomic railroad for a gut-bile duct-axis.
     J Hepatol. 2023 Apr 10:S0168-8278(23)00221-0. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     March 2023
141. 
     EASL-ILCA Clinical Practice Guidelines on Intrahepatic Cholangiocarcinoma.
     J Hepatol. 2023 Mar 22:S0168-8278(23)00185-X. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
142. RICCIUTO A, Kamath BM, Hirschfield GM, Trivedi PJ, et al
     Primary sclerosing cholangitis and overlap features of autoimmune hepatitis: a coming of age or an age-ist problem?
     J Hepatol. 2023 Mar 2:S0168-8278(23)00162-9. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
143. LAPITZ A, Azkargorta M, Milkiewicz P, Olaizola P, et al
     Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis and prognostication of cholangiocarcinoma.
     J Hepatol. 2023 Mar 1:S0168-8278(23)00159-9. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     February 2023
144. DUWE L, Munoz-Garrido P, Lewinska M, Lafuente-Barquero J, et al
     MicroRNA-27a-3p targets FoxO signalling to induce tumour-like phenotypes in bile duct cells.
     J Hepatol. 2023;78:364-375.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Biliary Tract Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum